# A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

> **NCT03430843** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 512 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03430843
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2020-12-01
- **Final completion:** 2022-12-28
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430843, "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03430843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*